The U.S. Food and Drug Administration (FDA) announced on October 20, 2026, the approval of the first generic version of the transdermal hormone therapy patch Climara Pro. The product, an estradiol and levonorgestrel transdermal system, is designed for once-weekly application in women with an intact uterus. This medication is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis.
Unlike estrogen-only patches, this system combines estrogen and progestogen in a single patch. The inclusion of progestogen is intended to mitigate the risk of endometrial hyperplasia, a condition that can arise from the use of estrogen alone. According to Michael Davis, M.D., Ph.D., Director of the FDA's Center for Drug Evaluation and Research, the once-weekly dosing schedule provides a convenient alternative to daily oral treatments, potentially improving patient adherence.
The FDA notes that the generic system is therapeutically equivalent to the brand-name product, which is manufactured by Bayer. The generic version is produced by Zydus Pharmaceuticals (USA) Inc. As with the brand-name medication, the generic patch carries specific contraindications, including histories of breast cancer, undiagnosed abnormal genital bleeding, active or past thromboembolic diseases, and hepatic impairment. Common adverse reactions reported include application site reactions, breast pain, headache, and vaginal bleeding.
